Table 1 Overview of breast cancer trials - the 'doubly tested trials'
From: Randomized adjuvant trials in oncology: a necessity or time-consuming luxury?
| Â | Stage IV response rates | Adjuvant setting DFS hazards |
|---|---|---|
Tamoxifen | 30 to 40% | 0.60 to 0.70 |
Cyclophosphamide (vincristine prednisolone) | 40 to 80% | 0.70 |
Anthracyclines versus cyclophosphamide | 20 to 30% | 0.80 |
Taxanes versus anthracyclines | 20 to 30% | 0.81 |
Aromatase inhibitors (letrozole) versus tamoxifen | 30 to 40% | 0.57 |
Trastuzumab versus placebo | 40 to 50% | 0.42 to 0.54 |
Curability | 0% | 15 to 40% |